Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
AssigneesThe Broad Institute, Inc., The General Hospital Corporation
InventorsASHWIN N. ANANTHAKRISHNAN, CHENGWEI LUO, VIJAY YAJNIK, RAMNIK J. XAVIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a relationship between microbial metagenomic structure and function and clinical remission with anti-integrin therapy induction; longitudinal trajectory of changes in the microbiome with maintenance treatment; and a comprehensive predictive model incorporating clinical and microbiome-related data to accurately classify treatment response.
Claims5
A method of treating a selected subject with an inflammatory bowel disease (IBD), comprising administering to the subject an anti-integrin therapy, wherein the subject is selected as having increased levels of Roseburia inulinivorans and/or a Burkholdenales species as compared to a control subject.
(canceled)
The method of claim, wherein the anti-integrin therapy is vedolizumab.
Dependencies are inferred from the claim text.